Gene therapy continues to receive a lot of investment, and a domestic pharmaceutical equipment company is accelerating its deployment

 Gene therapy is a new generation of precision therapy following small molecule and macromolecule targeted therapy.
It provides new treatment concepts and means for tumors, rare diseases, chronic diseases and other intractable diseases, and has the potential to be unattainable by ordinary drugs.
Long-term, curative effect
.
The "One Time Curing" Gene Therapy report released by KPMG on March 24 pointed out that under the background that cell and gene therapy has become one of the eye-catching emerging fields in the global biotechnology field, the field of gene therapy continues to gain support from investors and biopharmaceutical companies.
A lot of investment
.
The report pointed out that many biopharmaceutical companies are enhancing their market competitiveness through mergers and acquisitions and cooperation
.
The author learned that Novartis recently acquired Gyroscope Therapeutics, an ophthalmic gene therapy company, for $1.
5 billion
.
Novartis has completed its acquisition of Gyroscope Therapeutics, a clinical-stage gene therapy company focused on ophthalmology, for an upfront payment of $800 million ($587 million) and may require up to $700 million upon achievement of certain milestones ( $514 million)
.
Gyroscope's lead investigational gene therapy, GT005, is currently being evaluated in a Phase II clinical trial for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD)
.
Another example is Waters Corporation today announced that it has acquired the technology assets and intellectual property of Megadalton Solutions, Inc.
, an early developer of charge detection mass spectrometry (CDMS) technology and services, to expand its use in cell and gene therapy
.
The relevant person in charge of Waters said that macromolecular mass spectrometry using CDMS technology provides an important tool for the characterization, analysis and quantification of next-generation biological products such as cells and gene therapy, which is highly concerned by biopharmaceutical customers and biomedical research customers.
field
.
Analysts pointed out that the global gene therapy industry has been developing rapidly in recent years, and financing has been heating up day by day, including venture capital, private equity investment, and IPO.
development is important
.
Data shows that from 2016 to 2020, the total financing of the global gene therapy industry has increased significantly from US$5.
22 billion to US$19.
9 billion, with an average annual compound growth rate of nearly 40%
.
With the expansion of the gene therapy M&A market, the integration of gene therapy technology development and R&D resources will continue to be promoted, which will better promote the development of the gene therapy industry
.
Data shows that in recent years, the global gene therapy industry has begun to develop rapidly.
The market size has grown from US$50 million in 2016 to US$2.
075 billion in 2020, with an average annual compound growth rate of nearly 154%.
reached nearly $6.
6 billion
.
Nowadays, more and more innovative therapies are moving from laboratory to clinical application, and China has also become one of the regions with active clinical research on cell therapy in the world
.
Recently, China's "14th Five-Year Plan for the Development of Pharmaceutical Industry" in "Column 2 Pharmaceutical Industrialization Technology Research Project" proposed for biopharmaceutical technology: focus on the development of ultra-large-scale (≥10,000 liters/tank) cell culture technology, dual-function Industrialized preparation technology of new biological drugs such as antibodies, antibody conjugated drugs, polypeptide conjugated drugs, new recombinant protein vaccines, nucleic acid vaccines, cell therapy and gene therapy drugs, new drug delivery methods and new delivery technologies of biological drugs, new vaccine assistants agent
.
According to the "Planning", the field of cell and gene therapy has become a key development area
.
It is reported that domestic companies are also actively grabbing market opportunities in this field.
For example, Tofflon recently disclosed the plan to issue A shares to specific objects in 2022, showing that the number of non-public issuance of shares to no more than 35 specific investors should not exceed 188.
501112 million shares (not more than 30% of the company's total share capital before this issuance), and it is planned to raise not more than 3.
2 billion yuan, mainly for the enrichment of biopharmaceutical and cell gene therapy front-end product lines (DS) and the injection production line (DP) Innovation upgrade and production expansion
.
This also means that Tofflon is making a comprehensive layout in the field of cell gene therapy
.
The company said that it has a comprehensive product distribution in the field of cell gene therapy, with obvious first-mover advantages.
With the advent of CGT industrialization, it is expected to take over biopharmaceuticals and build the company's next growth curve.

.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.